A pivotal study modeled the progression from DNMT3A-driven CH to MPN and eventually AML in mice, suggesting that the transition to expansion of myeloid-restricted progenitors of mutant clones may be an early biomarker [59]. This evidence concerns the gene DNMT3A and myeloproliferative disorder.